Q-omics provides the consensus-scored HSD17B4 profile across patient tissues and cancer cell-line models. HSD17B4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HSD17B4 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, HSD17B4 protein abundance shows 30,177 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, THCA, and UCEC as cancer lineages where HSD17B4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSD17B4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSD17B4 survival associations across molecular data types. HSD17B4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSD17B4 RNA expression–survival associations across cancer types. High HSD17B4 expression shows unfavorable associations in CESC and HNSC, but favorable associations in KIRC, READ, MESO and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HSD17B4 RNA expression.
This table summarizes HSD17B4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 12. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HSD17B4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSD17B4 shows lower tumor expression in THCA, LUAD, LUSC, KIRC, KIRP and KICH. The THCA box plot shows higher HSD17B4 RNA expression in normal versus tumor tissue (log2 FC = −1.281, t-test p < 0.001).
This table shows molecular features associated with HSD17B4 in patient tissues and cancer cell lines. In patient samples, HSD17B4 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, HSD17B4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
